The limitations of this study are as follows: (i) lack of identification of HLA-G dimers and monomers in the peripheral plasma of cervical cancer patients; such analysis might help to corroborate the function of different HLA-G polymers; and (ii) lack of identification of shed HLA-G1 and soluble HLA-G5 in sHLA-G; assessing different sHLA-G isoforms might help for development of immunotherapy for cervical cancer. This evidence concerns the gene HLA-G and cervical cancer.